Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib (original) (raw)

References

1. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164–172.
   Article CAS PubMed Google Scholar
2. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820.
   Article CAS PubMed Google Scholar
3. Hochhaus A, Hughes T . Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 2004; 18: 641–656.
   Article PubMed Google Scholar
4. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J et al. Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment. Blood 2008; 111: 1039–1043.
   Article CAS PubMed Google Scholar
5. Druker BJ, Guilhot F, O’Brien S, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.
   Article CAS PubMed Google Scholar
6. O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J et al. In vitro activity of Bcr–Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500–4505.
   Article PubMed Google Scholar
7. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of _N_-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658–6661.
   Article CAS PubMed Google Scholar
8. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303–2309.
   Article CAS PubMed Google Scholar
9. Clopper CJ, Pearson ES . The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404–413.
   Article Google Scholar
10. Brookmyer R, Crowley JJ . A confidence interval for the median survival time. Biometrics 1982; 38: 29–41.
    Article Google Scholar
11. Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542–2551.
    Article PubMed Google Scholar
12. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399–401.
    Article CAS PubMed Google Scholar
13. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science 2001; 293: 876–880.
    Article CAS PubMed Google Scholar
14. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196.
    Article CAS PubMed Google Scholar
15. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR–ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690–698.
    Article CAS PubMed Google Scholar
16. Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlägel U, von Bonin M et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401–408.
    Article CAS PubMed Google Scholar
17. Thomas J, Wang L, Clark RE, Pirmohamed M . Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739–3745.
    Article CAS PubMed Google Scholar
18. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S . A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004; 279: 34227–34239.
    Article CAS PubMed Google Scholar
19. Quintas-Cardama A, Kantarjian HM, O’Brien S, Borthakur G, Bruzzi J, Munden R et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25: 3908–3914.
    Article CAS PubMed Google Scholar
20. SPRYCEL (package insert). Dasatinib Prescribing Information. Bristol–Myers Squibb: New York, NY. November 2007.

Download references

Acknowledgements

In addition to the authors, the following primary investigators also participated in this trial: Australia: C Arthur, S Branford (molecular analyses), A Grigg, J Seymour and K Taylor; Austria: P Valent; Belgium: A Bosly; Canada: D Forrest, C Gambacorti-Passerini and P Laneuville; Denmark: JL Nielsen; Finland: K Porkka; France: J-L Harrousseau, F Maloisel, M Michallet, J Reiffers and P Rousselot; Germany: C Bokemeyer, P Erben (molecular analyses) and T Fischer; Ireland: E Conneally and M O’Dwyer; Israel: A Nagler; Italy: E Abruzzese, F Castagnetti, F Ferrara, G Lambertenghi, V Liso, G Rosti, B Rotoli and G Saglio; Korea: D-W Kim; Netherlands: J Cornelissen and AVMB Schattenberg; Peru: J Navarro; Singapore: YT Goh; Spain: J Odriozola and JL Steegmann; Sweden: M Ekblom, B Markevarn, B Simonsson and L Stenke; Switzerland: A Gratwohl; UK: T Holyoake; USA: K Bhalla, S Bilgrami, B Cheson, R Collins, S Coutre, J Dipersio, S Durham, L Fehrenbacher, JK Giguere, FA Greco, HJ Khoury, M Lilly, J Lister, S Luger, A Maniam, J McGuirk, E Merriam, MS Murali, J Radich (molecular analyses), A Rapoport, CE Rivera, C Schiffer, R Strair and M Talpaz. Professional writing and editorial assistance, funded by Bristol–Myers Squibb, was provided by Josh Collis and Andrew Richardson. The funding for this trial was provided by Bristol–Myers Squibb.

Author information

Authors and Affiliations

1. III Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
   A Hochhaus & M C Müller
2. Department of Hematology–Oncology ‘L and A Seràgnoli,’ S Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
   M Baccarani
3. OHSU Cancer Institute, Oregon Health & Science University, Portland, OR, USA
   M Deininger
4. Department of Haematology, Hammersmith Hospital, Imperial College, London, UK
   J F Apperley
5. Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
   J H Lipton
6. The Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
   S L Goldberg
7. Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France
   S Corm
8. Division of Hematology/Oncology, San Francisco School of Medicine, University of California, San Francisco, CA, USA
   N P Shah
9. Department of Hematology, Hospital Clinic i Provincial, Barcelona, Spain
   F Cervantes
10. Division of Hematology/Oncology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA
    R T Silver
11. Department of Hematology, Oncology and Coagulation, University of Leipzig, Leipzig, Germany
    D Niederwieser
12. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
    R M Stone
13. Service Clinique des Maladies du Sang, Hôpital Saint-Louis, Paris, France
    H Dombret
14. Department of Medicine, University of Chicago, Chicago, IL, USA
    R A Larson
15. Clinical Research Center, CHU de Poitiers, Poitiers, France
    L Roy
16. Division of Hematology, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
    T Hughes
17. Bristol–Myers Squibb, Wallingford, CT, USA
    R Ezzeddine & A M Countouriotis
18. Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA
    H M Kantarjian

Authors

1. A Hochhaus
   You can also search for this author inPubMed Google Scholar
2. M Baccarani
   You can also search for this author inPubMed Google Scholar
3. M Deininger
   You can also search for this author inPubMed Google Scholar
4. J F Apperley
   You can also search for this author inPubMed Google Scholar
5. J H Lipton
   You can also search for this author inPubMed Google Scholar
6. S L Goldberg
   You can also search for this author inPubMed Google Scholar
7. S Corm
   You can also search for this author inPubMed Google Scholar
8. N P Shah
   You can also search for this author inPubMed Google Scholar
9. F Cervantes
   You can also search for this author inPubMed Google Scholar
10. R T Silver
    You can also search for this author inPubMed Google Scholar
11. D Niederwieser
    You can also search for this author inPubMed Google Scholar
12. R M Stone
    You can also search for this author inPubMed Google Scholar
13. H Dombret
    You can also search for this author inPubMed Google Scholar
14. R A Larson
    You can also search for this author inPubMed Google Scholar
15. L Roy
    You can also search for this author inPubMed Google Scholar
16. T Hughes
    You can also search for this author inPubMed Google Scholar
17. M C Müller
    You can also search for this author inPubMed Google Scholar
18. R Ezzeddine
    You can also search for this author inPubMed Google Scholar
19. A M Countouriotis
    You can also search for this author inPubMed Google Scholar
20. H M Kantarjian
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toA Hochhaus.

Additional information

This trial (trial no. CA180-013) is registered at http://www.clinicaltrials.gov.

Rights and permissions

About this article

Cite this article

Hochhaus, A., Baccarani, M., Deininger, M. et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.Leukemia 22, 1200–1206 (2008). https://doi.org/10.1038/leu.2008.84

Download citation

• Received: 27 February 2008
• Accepted: 07 March 2008
• Published: 10 April 2008
• Issue Date: June 2008
• DOI: https://doi.org/10.1038/leu.2008.84

Keywords